The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Vedolizumab for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease
Ivetta Danylesko and colleagues conducted a multi-center study evaluating the use of vedolizumab in severe steroid resistant (SR) gatrointestinal (GI) graft-versus-host disease (GvHD). SR aGvHD is a life-threating complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). vedolizumab is a gut-selective integrin blocker that targets the binding of integrin α4β7 to Mad CAM-1, blocking the homing of T cells to the GI endothelium and thus it may be beneficial for the treatment of intestinal GvHD. The results of the study were published ahead of print in Bone Marrow Transplantation.
Patients and methods:
- N = 29
- Median age = 55 years (range, 19–67)
- Early treatment group: 45% of patients received vedolizumab as second line of treatment
- Late treatment group: 55% of patients received vedolizumab after ≥ third lines of therapy
- SR GI aGvHD was defined as progressive/refractory disease failing methylprednisolone at a dose of 1–2 mg/kg
- Vedolizumab was administered at a dose of 300 mg IV, with planned repeated infusion at 2, 6 and every 8 weeks from then on
- Eleven patients also had liver and skin aGvHD
Key findings:
- Response rates in the early and late treatment groups:
- ORR (CR+PR) = 100% (13/13) vs5% (10/16), P = 0.012
- CR rate = 53.8% (7/13) vs25% (1/16), P = 0.047
- 6-month overall survival rate = 46% vs5%, P = 0.047
- The early treatment group had a higher chance of being off immunosuppression: 69.2% (9/13) vs8% (3/16), P = 0.007
- The early treatment group had less fatal infectious complications: 38.5% (5/13) vs5% (14/16), P = 0.006
The authors concluded by stating that their findings suggest that targeting integrin α4β7 may improve severe SR GI aGvHD, especially when vedolizumab is started early, as second line treatment after steroids failure. They further added that “the timing, role, and safety of vedolizumab should be further explored in prospective clinical trials.”
References